Process for the preparation of powder compositions

Patent metadata

Field	Value
Publication number	US-2020085901-A1
Application number	US-201716469826-A
Country	US
Kind code	A1
Filing date	Nov 30, 2017
Priority date	Dec 15, 2016
Publication date	Mar 19, 2020
Grant date	—

Abstract

Disclosed is a process for the preparation of powder compositions including a lipophilic extract of Echinacea spp., a lipophilic extract of Zingiber officinale and phospholipids. Also disclosed are powder compositions obtainable by the process and pharmaceutical, nutraceutical and cosmetic formulations including the compositions. Also described is a use of the powder compositions and formulations thereof in the prevention and/or treatment of inflammatory and painful states.

First claim

1 . A manufacturing process for preparing a powder composition comprising the following steps:
a) dispersing a lipophilic extract of Echinacea spp., or a botanical lipophilic extract containing alkylamides, and a lipophilic extract of Zingiber officinale in at least one polar organic solvent and mixing until a solution or a suspension is obtained; b) adding at least one phospholipid to the solution, or suspension, of the lipophilic extracts and mixing the mixture; c) removing the organic solvent to obtain the powder composition.

2 . A manufacturing process according to claim 1 , wherein the obtained powder composition is then calibrated.

3 . A manufacturing process according to claim 1 , wherein the lipophilic extract of Echinacea spp. is obtained from Echinacea angustifolia or purpurea.

4 . A manufacturing process according to claim 1 , wherein the other botanical lipophilic extracts containing alkylamides are lipophilic extracts of Zanthoxylum spp. or Acmella spp.

5 . A manufacturing process according to claim 4 , wherein the lipophilic extracts of Zanthoxylum spp. are obtained from Zanthoxylum bungeanum, Zanthoxylum piperitum, Zanthoxylum americanum and the lipophilic extracts of Acmella spp. from Acmella oleracea.

6 . A manufacturing process according to claim 1 , wherein the organic solvent is a polar protic solvent, like a, straight or branched, C 1 -C 8 alkyl alcohol, or a polar aprotic solvent, like a, straight or branched, C 1 -C 8 alkyl ester or C 1 -C 8 dialkyl ketone.

7 . A manufacturing process according to claim 6 , wherein the organic solvent is selected from the group comprising ethyl alcohol, ethyl acetate, acetone, isopropyl alcohol, isobutyl alcohol, and combinations thereof.

8 . A manufacturing process according to claim 1 , wherein the phospholipid is selected from lecithins derived from soy, sunflower or egg, phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, wherein the acyl groups are the same or different and are mostly derived from palmitic, stearic, oleic, linoleic, linolenic acids; and combinations thereof.

9 . A manufacturing process according to claim 1 , wherein the lipophilic extracts to phospholipid ratio ranges from 0.2 to 2.

10 . A manufacturing process according to claim 1 , wherein after step b) a second surfactant, other than lecithin, is added.

11 . A manufacturing process according to claim 10 , wherein the second surfactant is selected from the group comprising polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyglycerides, sorbitan fatty acid esters, sucrose palmitate, sucrose stearate, D-α-tocopheryl polyethylene glycol succinate, and combinations thereof.

12 . A manufacturing process according to claim 10 , wherein the phospholipid to second surfactant ratio ranges from 0.25 to 10.

13 . A powder composition obtainable by the manufacturing process of claim 1 .

14 . Pharmaceutical, nutraceutical and cosmetic formulations comprising a powder composition according to claim 13 and at least one physiologically acceptable excipient and/or carrier.

15 . A powder composition according to claim 13 for use in the prevention and/or treatment of inflammatory and painful states.

16 . The manufacturing process of claim 1 , wherein step a) further comprises applying heat.

17 . The manufacturing process of claim 16 , wherein step b) further comprises applying heat.

18 . The manufacturing process of claim 2 , further comprising grinding the powder composition to obtain a desired particle size distribution.

19 . The manufacturing process of claim 3 , wherein the lipophilic extract of Echinacea spp. is obtained from Echinacea angustifolia.

20 . The manufacturing process of claim 7 , wherein the organic solvent is selected from ethyl alcohol and ethyl acetate.

Assignees

• Indena Spa

Inventors

• Ronchi Massimo
• Frattini Elisabetta

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K9/501

  Inorganic compounds · CPC title

• A61K2236/53

  Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K36/758 Primary

  Zanthoxylum, e.g. pricklyash · CPC title